MYOV - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone and welcome to Myovant Sciences' First Quarter Fiscal Year 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Uneek Mehra, Chief Financial & Business Officer at Myovant. Please go ahead.

Uneek Mehra

Thank you, operator. fiscal you update us financial and Myovant's quarter thank of to results and first corporate Myovant's review and morning for today joining discuss of Good XXXX. year of the

Lauren Medical today's for Dr. Marek, Executive Officer; are Joining Merendino, Arjona, me Commercial Chief call, Chief Camilo Myovant's Dave Chief Officer; Officer. Juan and

call. available three slides or Today, quarter, investors.myovant.com. presented during be presentation. In the release press will referring website, be addition will representing first this June Relations issued webcast we that XXXX, on are to to after fiscal quarter Investor as our throughout today's earlier months today, the first XX, our today's QX, our ended the

with uncertainties call, this risks in results product from differ we materially and that all strategies, our products, will cause risks financials, could be conference beyond opportunities A and these candidates, actual and These which documents. control of to During SEC of disclosure expectations can statements. are these assumptions to involve and respect certain discussion of forward-looking our making our found statements. be include plans

now Executive In the Dave undertake does obligation I'll to addition, call any statements Officer. Chief made this call. Marek, Myovant over forward-looking Myovant's Dave? to any during update not turn

Dave Marek

million that $XXX.X Thank $XX.X revenues, revenue. off both quarter Myovant for ORGOVYX XXXX Myovant to us and by total our differentiated of million first you, is reach volume Uneek, with of net medicine. to with driven growth our and product advances good fiscal a regulatory marked year enable afternoon, recorded more including everyone. In and significant strong net patients start, MYFEMBREE

RYEQO growth broad antagonist treatment through treatment XX%. prostate With we're volume we GnRH men fibroids with prescribed one with European sequential of to in making And across of now brand we've in fibroids. our We the in great with prescription continue class new MYFEMBREE, MYFEMBREE to types and total that GnRH now women settings, continue number to and it for patient available of both U.S., leadership the uterine ORGOVYX efforts. XX therapy proud regulatory advanced progress demand for continued and uterine quarterly grow is is the cancer launched of range adoption with resulting more widely Outside reach a more the made countries, shares.

confident are FDA its with to our pleased meaningfully goal sNDA discussions pain the We Xth. year support to with for differentiated FDA sNDA withdrawal a our can XX, fibroid August FDA remain randomized expect efficacy X two The the FDA benefit potential PDUFA women of endometriosis. the date advancement We study sNDA. MYFEMBREE with and the in the the with therapeutic clinical and the In that for be option the on in to results symptoms, decision work to review show study. a XXXX. FDA PDUFA date term of LIBERTY with labeling become uterine women's for potentially goal setup January and to have MYFEMBREE treating continue longer June, MYFEMBREE from on endometriosis-associated from accepted profile the by closely data safety based respect announced of we our for Phase the MYFEMBREE We'll

therapy adult ORGOVYX to to This prostate oral only is Kingdom patients in sensitive deprivation hormone cancer. this and with meaningful I'm to with Europe. Moving androgen coupled Commission European in the April, oncology, excited that patients will as United first more across approval share for the now the bring advanced approval approved therapy

of upfront exclusive payment in received despite challenging in our This strong us commercialize Europe. QX $XXX financial partnerships $XX ended ORGOVYX pipeline. seeking continue we quarter to to Finally, our support environment, and expand MYFEMBREE committed fully a to Myovant. also activities, financing in its million, to agreement Accord And commercialization a for with enabling while be and macroeconomic includes a value ORGOVYX strategic the position for the driver license for cash from million

Lauren our call in Now, commercial a depth over I'll review of for to performance. more turn the

Lauren Merendino

Thank update our on MYFEMBREE ORGOVYX Today, the U.S. an in and Dave. provide performance you, our I'll launch on of the progress

and we're revenues of XX,XXX growth continued treated with advanced androgen drove strong have commercial start ORGOVYX as of and QX. demonstrating ORGOVYX quarter, to patient care now to been delivered men ORGOVYX for standard volume our in advancing of Let's our growth multiple QX, our also an demand report prostate utilization. fiscal Since prescriber performance. Further launching and proud fronts that deprivation XXXX, ORGOVYX on with continued this demonstrate approximately sequential of in growth, ORGOVYX January it progress cancer. the in product of illustrating we million net expansion demand. $XX XX% establishing

for role see As we at achieved net coverage established trends, we quarterly revenue the enabling patient look sales ORGOVYX affordable play important you to broad brand in success continues access. represents the by XX% an we've quarter-over-quarter can growth. The QX the in

out than out month. three fact, of paying ORGOVYX on patients In of per $XX pocket are four less

growth Our And the we new the of that the growth continue to with see us to were we will fiscal such to within low end net this quarter. starts remained expect brand fluctuations, as Due mid-XXs. be stay we and quarterly upper gross confidence future. this within near previously range Leading to to year. this to continue stated strong, range giving for range of account this this patient indicators in

market increase It's prescribers representing profile benefit types. of quarter, data important while the and This more spectrum launch is across have note analysis ADT to patients treated in the bit starts XX,XXX. prostate disease, have to overall. the patients ORGOVYX grew we of prostate and a confirms ORGOVYX's total initiating a since localized pharmacy a what clinical talk of represent patient see these XX% in Recent Let's this that patients. new additional the estimated an patients range cancer shows last that bringing over consistent these factors. to with a metastatic advanced of cancer, ORGOVYX quarter claims of half men compared our broad about clinically specialty XX% QX, analysis ORGOVYX which with X,XXX see patient

there XX% segments date. see our As XX% of The our are utilized from XX% seeing urologist. similar account volume treatment across quarter. reported of we we've accounts growth all overall network our volume delivery combined. importantly, the number driving the versus as we you accelerated our men be ADT dispensing experience of IDN impact this segment in And is half This ADT business well quarter remember, can reported this business ORGOVYX comes versus balanced an with year, last QX. dispensing with about quarter clinics, across collectively many that very opportunity the in to benefits XX% to more reported with Most to And This well, overall. this XX% of continued and ORGOVYX last by consistent of for each chart, quarter. distribution we quarter and and is the with being growth what what accelerated with with across market growth and having ORGOVYX help to to centers the Almost men as integrated types, account has coming with as the our patients. in volume X,XXX well our expansion continues of to is our XX% pie tremendous We're academic we primarily from see business, driven demonstrates from clinics, also growth the growth driven in And expand of substantial spectrum accounts prescriber primarily future. with seen this treated the the segment by it's segment XX% XXX,XXX which us oncologist. academic last over continues is

the MYFEMBREE, update milestone quarter. QX Now, launch to for turning another was

brand. to Within with we're the therapies brand with GnRH market been continue become share. this the class women have leader be treatment since momentum capturing total seeing Over treated also total fibroids, now MYFEMBREE in approved the for growing launch, prescriptions prescriptions, market of have in and to the X,XXX prescription of leader uterine XX% reflecting we new

a population that order prescription GnRH in commercial the first now uterine $X of XX%. XXXX in previously XX% patients new quarter, million treatment to the we been we it's which class. with Of MYFEMBREE launch revenue. execution to for with and QX, increase of our fibroids we've are differentiated believe a receiving demonstrates launch MYFEMBREE since in of A X,XXX patients, XXXX, antagonists this imperative expanding has patient demand total population sequential that paradigm, the stated, As our therapy, about new indicating In will MYFEMBREE's is broadening Since MYFEMBREE GnRH MYFEMBREE part of change commercial This that believe that easy June of since in grow quarterly prescribers benefit treatment. by clinical GnRH has volume the class that patient XXX%. used the we profile grown treatment has patients treatment. our over by launch treat net recognize to the starting MYFEMBREE of of class been making key is and these strategy increased access. receiving this represents to from XX%

therapies from month. of to patients the announced commercial or we coverage less new leader became paying approved with uterine Last established covered are of we in pocket commercial we've and benefit prescriptions quarter, XX% for the broad GnRH for per these We XX% out continue of to brand $X that lives fibroids. market

see XX% total has crossed that leader you which on The As our as differentiated approval XX% our become with our have strategy cross has now with and execution then a and as you we well. and on the in This we threshold customers threshold we year NBRx field speed prescriptions and crossed see leadership well is six our graph months the have the profile NBRx, the the is and threshold the market of with leader to It to commercial demonstrates post right a in can MYFEMBREE in impactful. become the launch, resonating share post have took that the left, at now TRX. continued can on been impressive. market TRX

our we in the will and change bleeding steadfast heavy fibroids that uterine women treatment belief paradigm their for menstrual to For with in we future. more remain and the these treatment provide continue reasons, effective

earnings overall on GnRH we now expansion expanded that fibroids. to ORGOVYX to In our drive MYFEMBREE is launch MYFEMBREE antagonists XXX% by abuse In XXX%. reported market last the share, to addition grown proud to market helping antagonist we're call, that uterine leading report of since GnRH in further had and the

as is making product. And the utilizing that patients class what shows serve reaching with increase In continued was now is play increasing reported a the XX% overall research shows uterine far many an a had role which was and XX% want prescribed continuing market MYFEMBREE decision. guidelines first Over also emphasize X,XXX needed in Ultimately, And with MYFEMBREE do will MYFEMBREE, antagonist addition quarter. fibroids the expansion GnRH this is selecting fibroids. women lack prescribers, to that continuing the to treatment information trend our can gynecologist to prescribers the to more these it's uterine for over women class. making the of And to class active when but growth for of for attract a they treatment uterine to catalyst new fibroids. importance who volume, decision lead ACPs last MYFEMBREE so. class that have their ACOG a from shared benefit to written

the we likely multi this launched treatment, research specific our are fulfill With that channel gynecologists in request. a of mid media mind, patient and shows consumer resonate designed campaign most Additionally, is a June, majority a efficiently with imperfect to in when engagement. campaign that take perfectly reach to who messages drive action. are increased The and awareness targeted to most to likely leveraging life these patient those requests

activation early believe are While redefine our activity, an indicators of part uterine fibroids. consumer showing care we patient impact is an and very and on strategy important to initial already that

class uterine overall. campaign on utilization patient expect growth accelerate activation We engage further fibroids with partners MYFEMBREE options treatment this that ACP for in continue to to will and and through their the drive patients

the As fibroids changing paradigm. uterine MYFEMBREE already is the treatment discussed, market we've evolving and

uterine and momentum continued gears to with building date women the our Shifting will and endometriosis. fibroids. progress care be able that to to Our confidence overtime, drives now advance we redefine for

with profile, and enabling our reduce for new will in continuing U.S. endometriosis looking us can to associated over opioids, what financial endometriosis well. grant were debilitating high to a affordable opportunity effective, current that pain, a often the women Uneek call treatment the know, Endometriosis to for they're significantly prepared impact medical endometriosis to you the remains fibroid we uterine accelerate of underscores review a surgery, approval have for for X perhaps and we their would paradigm pain. this in significant the sNDA provide quality into patients and need disease. and Shouldn't that the million symptoms, approximately quickly while need for unmet execution as reducing perspective a of efforts, easy strategic This ask given need for they to market, As to It impacts X gynecologists under patients. the be which is a life. the synergies, MYFEMBREE I uterine that shape launch they by in these is treatment have launch our for significant want unmet fibroids PDUFA which million in When currently associated need are treatments say now access. experience turn tolerable are and this FDA safety review. from This August. both date, MYFEMBREE

Uneek Mehra

today focus XX-Q in first Thank you, financial on earlier quarter. information. today and the the additional issued of release Lauren. for My a comments will press Form a refer highlight to performance Please

The near Part the the to expected QX of upper $XXX.X Myovant commercial XX% reflecting fluctuations first Let's in in gross which net Medicare sales demand D due deduction revenues volume the ORGOVYX range million. growth. net XX%, was revenue sequential for in quarter. approximately end was rebates. first of recorded net revenue quarterly was and ORGOVYX our $XX.X growth to total product million timing million, sequential net quarter the begin was with $XX revenue. quarterly quarterly XX% in

Consistent year. As we sequential the quarterly million demand was deductions in net related million to recognition million Pfizer payments. Pfizer, net $X.X with milestone gross the Lauren MYFEMBREE to first partial the and XX% collaboration $X to mid mentioned, continue reflecting to fiscal revenue growth. prior the regulatory commercial upfront $XX.X related ORGOVYX for for $XX expect uterine to quarter, recorded be of volume low this XX% million the million representing we from fibroids the revenue, recognition $XXX of received of partial payments to quarter,

received revenue, first million Accord payment we the of $XX recorded also we from the consisted upfront XXXX. in quarter, of which For Accord license May

for U.S. X from expenses of of or royalties other share due reduction the expense well of revenue the our of to first net Phase was related to tax sales to expenditures. was applicable implementation expense Section to to and the driven R&D $XX.X the was R&D was pertaining in in expense to The year primarily personnel sold, to quarter prior prior ORGOVYX comprised to commercialization the of to for costs Internal The These quarter Income Accord increase the income million period. profits billion, million the as increase was the the as MYFEMBREE in reflecting first $XX.X well the product on study Cost of payable compared completion the decrease became during comparable quarter. $XX higher higher Moving comparable U.S., of highlights The first activation $XX.X costs, MYFEMBREE, $X.X quarter in reflects the for out in MYFEMBREE comparable quarter Collaboration year's particularly SG&A study. the including the the period. $X.X in agreement. period. with as statement. the cost expense for million support Code year in prior SPIRIT Myovant costs, associated and was Myovant compared amortization for primarily a million related $XXX,XXX first first expenses bankruptcy to LIBERTY wind the for the ORGOVYX license HERO clinical in reflects activities the compared of XXX billion, amendments clinical by goods largely sales the of $XX first relugolix as patient amendments Takeda. million, and primarily of quarter Revenue XX% net Pfizer's

be per approximately quarter. $XX.X the loss for expense generated $X.XX a first XXXX fiscal of was loss million. net million our share the $XX total basis, quarter. million net in to for a tax expect to We Myovant $XX On

requirements, MYFEMBREE upon expect expected FDA. of opportunities, future the driven of are such first post-marketing environment, the support on XXXX the fiscal total promotional remains as SERENE of of million expenses X promotional targeted SG&A $XX.X of including Despite macroeconomic to Phase our marketable We and under well in million quarter spend, facility and for first to agreed in on by annualization financing higher primarily the Pharma, in activation the we expenses balance relugolix strong. committed us to marketing commercialization quarters loan by with and the largely challenging spending cash, the and MYFEMBREE. capacity quarter, patient comprised than as the than largely million as ORGOVYX marketable with as the Sumitomo ahead, sheet the of MYFEMBREE securities driven study, R&D shareholder. fiscal and first ongoing cycle ended and U.S., be to cash majority Myovant's XXX and higher XXXX securities, the of remaining Looking of $XXX.X quarters extended future by be quarter marketing expenses life overall

closing an commercialization position growth turn drivers. liquidity as current potential in with ORGOVYX the excellent our and remarks. Dave I MYFEMBREE certain in with commercial collaboration well from to on increase revenues, expenses, back over future financial of anticipated payments, key additional successfully our relugolix-related Pfizer, Our as partners, now position and and will development deliver it puts Myovant sharing to milestone coupled key for

Dave Marek

drive prostate advance to our settings broad well patient Lauren. Uneek treatment as and you, strong We're execution we to today care to types we commercial throughout cancer. uterine delivering and while across on aspiration our in XXXX. class MYFEMBREE, We positioned differentiated helping look women the ORGOVYX with we profile adoption expanding a new Myovant clinical to are focused believe demonstrate leadership continue advanced fibroids. is performance and antagonist standard redefine create as as extend market From of care for Thank for to us of GnRH

by globally patient the partnerships allows execution, our labeling balance driving will tomorrow. Our the And to our with for We're outside commercial our in impact as associated to U.S. if has MYFEMBREE for our building sNDA forward bringing continue to in for August us this to its our day. and reach FDA strong confident engaging PDUFA of decision and application meaningful endometriosis later expand discussions sheet forward Canada. strategic quarter. and and FDA to grow approved, we while look X this on patients continue We pain look remain therapy the Europe we

additional your exciting milestones to I'll And attention begin later to the for have year. session. intend to turn the over mentioned, new share operator we Thank ahead. potential as call on you pipeline details the programs previously We this Q&A and

Operator

Nadeau [Operator coming the is Cowen. Instructions] with our Now Phil line question first of from

Your line open. is

Phil Nadeau

Dave, endometriosis refer First, label one the to. expansion you just on that

had in labeling been negotiations, deficiencies information any of its that does As the Myovant any light deficiencies now have part in got the resolved? communication more like seem on the and it identified FDA

Dave Marek

Camilo let that. Thanks, Phil. Juan address I'll

Dr. Juan Camilo Arjona

very on to remain Yes. the and final decision of Phil, through with we as you there's are in review, the the the indication FDA profile PDUFA continue FDA. forward that we've date. MYFEMBREE labeling making on is usually with negotiations, to and commenting their our FDA we look know, the What collaborate we no the confident appropriate entered discussions don't consider reporting ongoing

Phil Nadeau

uptake slower? in assuming we there a features in gains the launch, rate one market trajectory which you August, Are Could that of MYFEMBREE faster unique endometriosis? expect the approval share make fibroids at of any either or would on same second of uterine share impressive. and endometriosis captured been then number has the the And

Dave Marek

a think, in what this let of excited to it. that. potential endometriosis. this, I'll same Lauren, and looking parallels lead let endometriosis. looking the I We address do Well, Lauren, characteristics some is you but lot for We're in they're customer get in really fibroids we uterine approved a color base you of additional is for add about think to that the the I'll kind if

Lauren Merendino

our approval, launch. for prepared believe that Yes, and clinical it's we're our market. should market, is opportunity a is excited about our that in very but team FDA favorable the the different grant We profile

about excited the So opportunity. we're

that have one. payer we endometriosis. already established some uterine extension. because in factors payer think beneficial coverage are a From this are for fibroids, have considered MYFEMBREE line Additionally, in there And already are you and set would we us that be number positively established perspective, we that up fibroids, for a is

coverage. So we we move payer quickly secure can believe to

of we here, think has Secondly, well we've endometriosis their of prescribers then that experience that and got synergy And that to that their prescribers. will have both translate there's been a positive their finally, the indications tremendous now existence, that think with there's experience base MYFEMBREE we treating because high patients. across overlap

we'll there's And so synergy, able opportunity to that a tremendous therefore, realize from the field perspective, and quickly. be

Phil Nadeau

financial One remind think we in years, Can has from last for us I whether if taxes said and the XXXX. Myovant in in taxes million us $XX million why you profitability? achieved taxes on your future should remarks question XXXX prepared understand taxes, not you I model the even to $XX

Dave Marek

Uneek? Yes,

Uneek Mehra

I defer later a of as approach years this sort that the being better companies remarks, think legislation you'll amendments per now but that. amendment still we've mean be I than Section conservative that that book could to prudent possibility and taxes across to and XXX the seeing the more I taken with prepared think,

of also sort our policy We a have of doing deferred tax.

those fail, we valuation it's We for that. full taxes to reserved booking 'XX, of our line combine start sort two of exposure. have fiscal with appropriate a for the you When in thought sort

in those we we right to Now our have we outer the that give of well for guidance we applicability least taxable but have depending to the year years, this at should amendments determine year, to still as as thought as now. these sort visibility income on regards that

Operator

coming Brian with Baird. is line of from the question next Our Skorney

is line open. Your

Brian Skorney

that talk could to is, include you the and hoping can think how through you potentially just the about think I was from data in you think ramp two just Orion, safety us understand sNDA sort differentiate maybe help you near-term ORGOVYX LIBERTY you commercial of up? impacts how how any year important

Dave Marek

start on? Camilo Juan with one I Lauren, don't you could if Why add and then

Dr. Juan Camilo Arjona

demonstrated for, just into think second continuing LIBERTY MYFEMBREE showed. with I or placebo. study, how year demonstrating the therapy this led how remember taking withdrawal long-term stopping we randomized heavy was the have the efficacy. placebo that treatment this And maybe in the of the data This in therapy We've Therefore, that And and group this retreating where we bleeding, regain what menstrual already to of we submitted from patients patients our we that, should study seen. the control randomized returning we program. with MYFEMBREE provides data.

also generated density. data including We safety additional mineral the long-term, for bone

data look review. data fibroids So, of for remind the to is that label. antagonists. and those year now GnRH the least in FDA, uterine term provided we've capturing in some the for concepts the course, two show also longer the efficacy of pending I'll safety you about for that showed for and this this We program only has

Dave Marek

program competitive going and look Brian, they outset, could at Yes, could uterine you if of I to help treat fibroids. chronic understand, to and from And think also, looking that establish were terms they from to Lauren? the a perspective, We a longer condition, in clinicians that's a know that, were term, a when very we extend if matches therefore, it therapeutic would then option that. have that how

Lauren Merendino

review competitive of label speak to differentiator that be are we along safety I to with to us a it things would under say the profile the use comes FDA. enable and Well, where perspective, product But this from always a careful the get we're in with and and when efficacy that. long-term that our I would mean,

Brian Skorney

a a as follow-up, obviously two I it's study. just quick mean, year Maybe

the think doesn't is around you that of in use? the terms is a any continued limits that think risk months it a Do Or that's enough loss XX that? you way But limitation there to thought limitation maybe feasible? bone question address the get eventually label. of on So about do

Dave Marek

for data you looking provided we get uterine running the also to to that before a in us, to mind top of are, FDA study now the coming in get your course we will provided We were fibroid by of are could the data know, certainly is the at and we approved to future, will said we weeks. the or if your we've to Brian, as we for how as Yes, that. endometriosis, that potentially of started get But requirements running with marketing any us future to combined endometriosis allow data MYFEMBREE. four in that data years hard data have address have potentially think will how it's the But something FDA it's to of via BMP what views. speculate able think that of the we constantly duration we to again, the potentially FDA post impact up the will until And on may that provide were on we to it. data us it. believe But all for to

Operator

with from JPMorgan. is our coming the line Joseph And Eric of next question

Your line open. is

Eric Joseph

sort follow-up indications could in like and might expect How on have these of couple criteria trying the like assume in discussions that lower that safe of endometriosis? Or current of of relaxing lowering labeling ongoing more level might label some endometriosis create the of worrying and sounds total you're MYFEMBREE. a that to in terms if uptake? U.S. It what current uterine endometriosis peer-review quickly the you visibility are will is in it it And already sort that's for limitation, on between duration has T to to approved? or these like display MYFEMBREE it to try is of approval? a label endometriosis fibroids? restrictive it be a you conservative shorter I expecting contributor Just assuming cycle label? lead is look And really a then, in uptake to language, endometriosis more to a Do possible

Dave Marek

Eric. you, thank well, Yes,

you any go. we really think on anticipate where I regarding label don't know FDA want to as speculation might the

same accustomed brand endometriosis. underway in plan endometriosis. there's applied benefits to same a one we who simplicity on As that dose, the be gynecologist prescribing If the key We are the of we endometriosis. dosing, and approved as and think that discussions transfer the regarding uterine and value they've If uterine were over that MYFEMBREE really Camilo are endometriosis our and a same FDA we approved, assessment get can strong exists. one for of physicians could fibroids. make mentioned, believe experience day that we think that's to Juan Remember once of pill their to the mentioned, simplicity to already advantage a fibroids, with they'll gained really foundation was easily on huge

excited significant help that if the we launch us. really think about to for women get we very and we're to So, the with is opportunity very fibroids potential point, uterine

Eric Joseph

of between I guess, to do ability uterine endometriosis there or fibroids visibility sort that? in and And the terms updates of is

Dave Marek

I of mean, Lauren, awareness you for about think for significantly physician want discussions fibroids is levers payers the standpoint translate high and maybe pretty other will with endometriosis. uterine that and to very to MYFEMBREE already potential talk over I of update? from

Lauren Merendino

I to just Eric, asking. the this around data is indications? Is that of what transparency Well, between what clarify, asking? that's the believe question the you're data, the you're

So, we has analysis will require so have out more it it the far. ability data. will the But to than separate

question? but then for need apply be additional to that one course, and indication, product your there. single a have visibility. prescription we that have the We is we able with every that Does indication. to do may In prescription answer of having the So know claims we'll to data, analysis will lost future,

Operator

next Our Madhu Instructions] the with Goldman from line coming of Kumar [Operator question is Sachs.

Madhu Kumar

burn. cash on really one first Our

in through potential recognition the and this runway Accord endometriosis thinking cash about ongoing burn excluding of launch So the given quarter kind the of kind you how of of the kind are revenue? the burn

Dave Marek

for with that I'll it's over same, then turn Uneek the remember, given base. MYFEMBREE current I'll thing largely the promotion start are to if I physician approved efficiencies same we think. endometriosis, have we One it to the our really and

any that. the around no have plans We significant force activities field or to other expand

reference that's you when So remember efficient would within efficient us endometriosis, very or and be we just have very a for commercial engine fit Uneek? that our now. launch

Uneek Mehra

net just I of from you Madhu And color, to the financials. about will think million $XX cash notice burn get

Accord payment. course, we've from benefited Of the of the receipt upfront

you back, burn. cash about So XXX take so it's if sort that or of

go that payments resource that's the of that out. first approved we I a with when think comfortable ORGOVYX. the When and then in as to flag way. feel endometriosis want I expect million burn milestone our have, coming fiscal cash of cash uterine remainder personnel we we at I have in from look think course, we of typically the endometriosis, we Now for related be able would August, quarter the should we have we year, to higher will pretty both because fibroids, $XXX get And allocate that year then Pfizer do

again cash for with comfortable is share into overall Pfizer financial in cost with sheet fiscal forecast. continuing balance have, this payments we factored very key that on we the our also So milestone our position, strength driver feel our year. the flow But our for

Madhu Kumar

quarters. the So kind around of current another ORGOVYX was question in

how forward quarters? the seen few quarters rate growth everything in of to what going revenue of ORGOVYX last given next go is and few you've kind So of trajectory over growth the the like

Dave Marek

quarter to about but Well, provided the guidance see. the remainder continued quarter very know, as Madhu, we of for year, starts, haven't excited we new patient we're this you

to we patients mentioned, step another for up ORGOVYX. Lauren As took significant XX,XXX

this patient to both settings we're broad And adding see adoption treatment as as types. continue well we For more across quarter, accounts.

ORGOVYX. we very is we about So, are optimistic for how shaping And momentum up that about have. continued excited this year the very we're

Operator

And our Securities. line is Ruiz from next Roanna with question SVB of coming

Your line open. is

Roanna Ruiz

one switch for So then and question ORGOVYX. I'll to MYFEMBREE

give for endometriosis? for August to goes approved Particularly, net gross more through for a detail remainder it's gets the evolve us on So little MYFEMBREE, might assuming it's be how and year? the can the to of you MYFEMBREE

Dave Marek

want Lauren, to take that? do you

Lauren Merendino

Yes.

a gross access. our a And to net great for to gross to by make our to from primarily patients. for easy and product experience first So that's both our physicians is strategy net perspective, driven

point continue believe today so, that's to to order and and important have in strategy uterine our tomorrow. growth trajectory continue in at with this that physician in endometriosis the we and gain fibroids product hopefully And to experience

gross far as to as guidance leave I'll on So, actual net, that to Uneek. the

Uneek Mehra

still just year. Yes, I know, MYFEMBREE beyond of sort one up covering getting

can Lauren fluctuations there as yet, are focus still happening. I'll big of commercial as And said, rebates are right to don't co-pays. guidance, color and comfortable we what ORGOVYX So, now, drivers that gross our the feel Lauren our imagine net The as said is, a unlike giving our to MYFEMBREE improve, patient you guidance, ORGOVYX the add accumulation, see more should to sure need on have making through a overtime for for MYFEMBREE. with that but we we right sort elements now only and those is sort be trends satisfied, patients of of able then are done to still of that yet and come not time which but

Roanna Ruiz

account credit academic these curious, curious, relative et IDN, prescribing same stay could using that your I are us ORGOVYX clinics, walked dispensing do know distribution the share types like stakeholders you forward? cetera. and or view, in ORGOVYX, for think through going centers, I of was you And the different also I of shifts was the

Dave Marek

Lauren?

Lauren Merendino

very good question. Yes,

as growth clinics. We provided we continue be trajectory quarter. I mean, will the for would that to with our the far say the where dispensing strongest see, see I as rates urology I

can't are the So you growth in the might drivers, future. biggest don't term. like clinics longer dispensing clinics share look I our the outpace academic what will I crystal But have dispensing tell in IDNs the a in ball. the but

Dave Marek

think utilization urologists pleased believe pull you of because having We such when lot men very patients. uptake just Roanna over ADT through a the and about to who Yes starting therapy, of start we starts new that really new that the by we're from with will time. are really oncologists urologist are strong for

will now with that think time. we over So, not oncologist with us only urologist help help even accelerate but

Operator

Evercore ISI. the The next of line question Clark-Gartner with from is Gavin coming

open. is line Your

Gavin Clark-Gartner

just I had two.

on First MYFEMBREE.

protocol. adjusted just the the trial put you Can you wanted? year remind last the on us So FDA hold BMD what monitoring was as the and changes free

Dave Marek

Camilo? Juan

Dr. Juan Camilo Arjona

couple things. Yes, of Gavin, there a were

in that we fibroids changed target population an healthy to endometriosis, uterine that with indication which population population women the initially, discussion the or seeking the You After the made major we study then, the sign. to are context is added Those and for of we our that and was current requiring. And and now BMD monitoring FDA the changes endometriosis the the the remember of otherwise trial label FDA, were that hopefully future running for approved. in is we've contraception. if women with may

Gavin Clark-Gartner

ORGOVYX, noticed month, pharmacy made we And so poor. has IQVIA then the network change the that captured you last script pretty specialty on which

on So that the elaborate making just rationale be seems wondered, switch? can for to I'm if you Symphony consistent.

Dave Marek

Lauren? Absolutely.

Lauren Merendino

Yes.

So which SPs Bioservices, of the was us back two one in CVS in our April, acquired network.

we in distribution order us to Bioservices. positive. feedback transition our has business through independent over July. and to And switched SPs, complications has been needed to OncoXXX maintain tremendously we so very And from transition at no There's model significant the The or been our gone disruptions the customer smoothly. of the beginning

products with lot OncoXXX in they the on other so past, In a fact but we've experience and have on nothing the of positive feedback heard transition.

Operator

turn I Mr. remarks. call the David closing to back will now over Marek for

Dave Marek

well sensitive to care our We redefine committed patients in hormone for to Thank health that remain women's We're and we serve mission you, the cancers. operator. in positioned.

differentiated We have growth. therapies generating significant two

pipeline now, have balance into to value. sheet have only not enable our long-term deliver to opportunities but future. We we a strong efforts the And sustainable

thank forward joining for our to on updated So, you Have much day. us. you I very a look keeping progress. good

Operator

and Ladies your earnings XXXX Sciences fiscal Thank of quarter for Myovant participation. concludes first gentlemen, you this conference call.

disconnect. now may You

Myovant Sciences (MYOV) 28 Jul 222022 Q1 Earnings call transcript